uniQure N.V. (QURE)
| Market Cap | 2.87B +255.0% |
| Revenue (ttm) | 18.09M -10.4% |
| Net Income | -208.87M |
| EPS | -3.49 |
| Shares Out | 68.75M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,811,025 |
| Open | 45.99 |
| Previous Close | 45.17 |
| Day's Range | 41.15 - 46.10 |
| 52-Week Range | 8.73 - 71.50 |
| Beta | 0.90 |
| Analysts | Strong Buy |
| Price Target | 64.47 (+54.2%) |
| Earnings Date | Jul 28, 2026 |
About QURE
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in phase I/II clinical study for the treatment of Huntington’s disease. The company also develops AMT-260, which is in phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in phase ... [Read more]
Financial Performance
In 2025, uniQure's revenue was $16.10 million, a decrease of -40.64% compared to the previous year's $27.12 million. Losses were -$198.97 million, -16.94% less than in 2024.
Financial StatementsAnalyst Summary
According to 13 analysts, the average rating for QURE stock is "Strong Buy." The 12-month stock price target is $64.47, which is an increase of 54.20% from the latest price.
News
uniQure price target raised to $80 from $50 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on uniQure (QURE) to $80 from $50 and keeps a Buy rating on the shares. The firm believes the June 17 regulatory update…
uniQure Announces Closing of Upsized Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares
LEXINGTON, Mass. and AMSTERDAM, June 25, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs,...
uniQure price target raised to $68 from $35 at Mizuho
Mizuho raised the firm’s price target on uniQure (QURE) to $68 from $35 and keeps an Outperform rating on the shares. Following a recent FDA Type B meeting, the firm…
uniQure 4.95M share Spot Secondary priced at $45.50
The deal size was increased to $225M from $150M and priced below the last closing price of $49.04 per share. Leerink and Stifel are acting as joint book running managers…
uniQure Announces Pricing of Upsized $225 Million Public Offering
LEXINGTON, Mass. and AMSTERDAM, June 23, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs,...
uniQure rises 7.6%
uniQure (QURE) is up 7.6%, or $3.35 to $47.74.
uniQure announces $150M offering of common stock
Leerink Partners and Stifel are acting as bookrunning managers for the proposed offering.
uniQure Announces $150 Million Proposed Public Offering
LEXINGTON, Mass. and AMSTERDAM, June 22, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs,...
uniQure reports preliminary data on first cohort in Phase I/IIa trial of AMT-260
uniQure (QURE) announced initial six-month follow-up data on the first, low dose cohort of six patients in its ongoing Phase I/IIa trial of an investigational gene therapy candidate, AMT-260, for…
uniQure Announces Preliminary Data on the First Cohort in the Phase I/IIa Clinical Trial of AMT-260 in Refractory Mesial Temporal Lobe Epilepsy
~ AMT-260 was generally well-tolerated with no serious adverse events observed to date, with early biological signals of potential therapeutic activity ~
Barclays upgrades uniQure, calls BLA submission ‘major positive’
As previously reported, Barclays upgraded uniQure (QURE) to Overweight from Equal Weight with a price target of $65, up from $25, calling yesterday’s update around plans to file a BLA…
uniQure price target raised to $70 from $36 at Leerink
Leerink raised the firm’s price target on uniQure (QURE) to $70 from $36 and keeps an Outperform rating on the shares. The firm caught up with uniQure management following Wednesday’s…
uniQure price target raised to $65 from $35 at RBC Capital
RBC Capital raised the firm’s price target on uniQure (QURE) to $65 from $35 and keeps an Outperform rating on the shares. The company announced earlier that the FDA is…
uniQure upgraded to Overweight from Equal Weight at Barclays
Barclays upgraded uniQure (QURE) to Overweight from Equal Weight with a $65 price target
uniQure price target raised to $46 from $14 at Goldman Sachs
Goldman Sachs analyst Salveen Richter raised the firm’s price target on uniQure (QURE) to $46 from $14 and keeps a Neutral rating on the shares. Shares moved sharply higher after…
UniQure to seek FDA approval for Huntington's disease gene therapy after previous clash with agency
UniQure said it plans to seek approval for its experimental gene therapy for Huntington's disease. The announcement comes months after UniQure became embroiled in a public debate with FDA leaders over...
uniQure upgraded to Overweight at Cantor Fitzgerald after BLA filing news
As previously reported, Cantor Fitzgerald upgraded uniQure (QURE) to Overweight from Neutral with a price target of $61, up from $18, after the company announced plans to submit a biologics…
uniQure upgraded to Overweight from Neutral at Cantor Fitzgerald
Cantor Fitzgerald analyst Kristen Kluska upgraded uniQure (QURE) to Overweight from Neutral.
What made uniQure stock nearly double on Wednesday?
uniQure (QURE) stock is ripping higher this morning after the biopharmaceutical firm announced a major regulatory breakthrough with the FDA for its Huntington's disease gene therapy AMT-130. As invest...
This Biotech Stock Is Surging 66% on Surprise Good News From FDA
Gene therapy maker uniQure is one step closer to marketing its treatment for Huntington's disease.
uniQure AMT-130 update ‘materially positive,’ says H.C. Wainwright
H.C. Wainwright analyst Patrick Trucchio reiterates a Buy rating on uniQure (QURE) after the company announced that, during a recent Type B meeting, the FDA communicated that the three-year analysis…
ClearPoint Neuro up 32% after uniQure announces plan for AMT-130 BLA submission
Shares of ClearPoint Neuro (CLPT) are up $4.32, or 32%, to $17.66 in pre-market trading after partner uniQure (QURE) announced during a recent Type B meeting with the FDA that…
uniQure up 75% after announcing plan for AMT-130 BLA submission
Shares of uniQure (QURE) are up $20.31, or 75%, to $47.30 in pre-market trading.
UniQure gets FDA green light to file for Huntington's gene therapy approval
Dutch drugmaker UniQure said on Wednesday the U.S. Food and Drug Administration has agreed that data from a mid-stage study could support an accelerated approval filing for its gene ther...
uniQure Announces Plan for BLA Submission for AMT-130 in Huntington's Disease
~ 3-year analysis from the Phase I/II study can serve as the primary basis of a Biologics License Application for accelerated approval with FDA ~